TITLE

Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)

AUTHOR(S)
Pettersson, Billie; Ambegaonkar, Baishali; Sazonov, Vasilisa; Martinell, Mats; Stålhammar, Jan; Wändell, Per
PUB. DATE
January 2010
SOURCE
BMC Public Health;2010, Vol. 10, p737
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Data on the prevalence of dyslipidemia and attainment of goal/normal lipid levels in a Swedish population are scarce. The objective of this study is to estimate the prevalence of dyslipidemia and attainment of goal/normal lipid levels in patients treated with lipid modifying therapy (LMT). Methods: This longitudinal retrospective observational study covers time periods before and after treatment. Data were collected from 1994-2007 electronic patient records in public primary healthcare centers in Uppsala County, Sweden. Patients were included if they had been treated with LMT and had at least one lipid abnormality indicating dyslipidemia and if complete lipid profile data were available. Thresholds levels for lipids were defined as per Swedish guidelines. Results: Among 5,424 patients included, at baseline, the prevalence of dyslipidemia (≥1 lipid abnormality) was by definition 100%, while this figure was 82% at follow-up. At baseline, 60% had elevated low-density lipoprotein (LDL-C) combined with low high-density lipoprotein (HDL-C) and/or elevated triglycerides (TG s), corresponding figure at follow-up was 36%. Low HDL-C and/or elevated TGs at follow-up remained at 69% for patients with type 2 diabetes mellitus (T2DM), 50% among patients with coronary heart disease (CHD) and 66% among patients with 10 year CHD risk >20%. Of the total sample, 40% attained goal levels of LDL-C and 18% attained goal/normal levels on all three lipid parameters. Conclusions: Focusing therapy on LDL-C reduction allows 40% of patients to achieve LDL-C goal and helps reducing triglyceride levels. Almost 60% of patients experience persistent HDL-C and/or triglyceride abnormality independently of LDL-C levels and could be candidates for additional treatments.
ACCESSION #
57223774

 

Related Articles

  • LIPIDS AND ATHEROSCLEROSIS. Đerić, Mirjana; Stokić, Edita; Vučković, Biljana; Kojić-Damjanov, Sunčica; Čabarkapa, Velibor // Jugoslovenska Medicinska Biohemija / Yugoslav Medical Biochemist;Dec2006, Vol. 25 Issue 4, p325 

    Lipids play a pivotal role in the atherogenesis, starting from initial changes. Their predictive value in coronary heart disease and development of novel therapeutic strategies is an increasingly addressed issue nowadays. LDL particles are fundamental, because reduction of LDL-cholesterol was...

  • Prevalence and pattern of lipid disorders in Saudi patients with angiographically documented coronary artery disease. Al-Shehri, Abdullah M. // Journal of Family & Community Medicine;Dec2014, Vol. 21 Issue 3, p166 

    Objective: The aim of the study was to assess the prevalence and patterns of dyslipidemia in Saudi patients with angiographically documented coronary artery disease (CAD). Materials and Methods: This is a cross-sectional, hospital-based study, which was conducted on all Saudi patients who...

  • Endothelial Microparticles (EMP) for the Assessment of Endothelial Function: An In Vitro and In Vivo Study on Possible Interference of Plasma Lipids. van Ierssel, Sabrina H.; Hoymans, Vicky Y.; Van Craenenbroeck, Emeline M.; Van Tendeloo, Viggo F.; Vrints, Christiaan J.; Jorens, Philippe G.; Conraads, Viviane M. // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Background: Circulating endothelial microparticles (EMP) reflect the condition of the endothelium and are of increasing interest in cardiovascular and inflammatory diseases. Recently, increased numbers of EMP following oral fat intake, possibly due to acute endothelial injury, have been...

  • Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by In Vivo High-Resolution CMR - a comparative analysis. Grimm, Jochen M.; Nikolaou, Konstantin; Schindler, Andreas; Hettich, Reinhard; Heigl, Franz; Cyran, Clemens C.; Schwarz, Florian; Klingel, Reinhard; Karpinska, Anna; Chun Yuan; Dichgans, Martin; Reiser, Maximilian F.; Saam, Tobias // Journal of Cardiovascular Magnetic Resonance (BioMed Central);2012, Vol. 14 Issue 1, p80 

    Background: Components of carotid atherosclerotic plaques can reliably be identified and quantified using high resolution in vivo 3-Tesla CMR. It is suspected that lipid apheresis therapy in addition to lowering serum lipid levels also has an influence on development and progression of...

  • Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV. Talwalkar, P. G.; Sreenivas, C. G.; Gulati, Ashish; Baxi, Hemang // Indian Journal of Endocrinology & Metabolism;Jul/Aug2013, Vol. 17 Issue 4, p628 

    Adult Treatment Panel (ATP), an expert panel to supervise cholesterol management was set up under the aegis of National Cholesterol Education Program (NCEP) in 1985. Since then NCEP-ATP has been revising and framing guidelines to enable clinician to deliver better treatment to cardiovascular...

  • Endothelial Microparticles (EMP) for the Assessment of Endothelial Function: An In Vitro and In Vivo Study on Possible Interference of Plasma Lipids. van Ierssel, Sabrina H.; Hoymans, Vicky Y.; Van Craenenbroeck, Emeline M.; Van Tendeloo, Viggo F.; Vrints, Christiaan J.; Jorens, Philippe G.; Conraads, Viviane M. // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Background: Circulating endothelial microparticles (EMP) reflect the condition of the endothelium and are of increasing interest in cardiovascular and inflammatory diseases. Recently, increased numbers of EMP following oral fat intake, possibly due to acute endothelial injury, have been...

  • Why Does The Lipid Hypothesis Persist?  // Health & Stress;2002, Issue 8, p7 

    Explains the reasons for the persistence of the belief that cholesterol causes coronary heart disease. Lipid theory; Potential market for cholesterol lowering drugs; Possible role of homocysteine on coronary heart disease.

  • Trends in Lipid Management Among Patients With Coronary Artery Disease. Massing, Mark W.; Foley, Kathleen A.; Sueta, Carla A.; Chowdhury, Mridul; Biggs, David P.; Alexander, Charles M.; Simpson Jr., Ross J. // Diabetes Care;Apr2003, Vol. 26 Issue 4, p991 

    OBJECTIVE — To examine lipid management trends for coronary artery disease (CAD) patients with and without diabetes in order to determine whether those with diabetes are beginning to receive aggressive lipid management consistent with their elevated risk. RESEARCH DESIGN AND METHODS...

  • Statins being prescribed for those `least in need'. Christie, Bryan // BMJ: British Medical Journal (International Edition);03/27/99, Vol. 318 Issue 7187, p827 

    Discusses statin as treatment for coronary heart disease in Great Britain. Information on a consensus conference on coronary heart disease; Issue of lowering lipids to prevent vascular events; Problem with the distribution of statin; Need for extra resources in areas of deprivation;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics